Joint Open Letter Calling Novartis to cease seemingly endless legal process in India
22. February 2011
In a joint Open Letter sent last Tuesday to Novartis’ President, Dr. Vasella, the signatories voiced their concern regarding Novartis’ persistent legal actions in regards to the patent application for Glivec (Gleevec in the USA), a vital medicine in treating relatively rare forms of leukaemia and gastro-intestinal tumors.
Despite three consecutive patent refusals pronounced by the Indian justice authorities since 2006, the pharmaceutical giant, through an appeal to the Supreme Court in August 2009, is insitant in its attempt to challenge the Indian Patent Law. The Open Letter strongly urges Novartis to drop this pending case. Domestic NGOs have organised simultaneous protest events throughout India, and will remain mobilised until the next hearing of the Glivec case at the Supreme Court scheduled for 19 April this year.
The Open Letter also urges Novartis to abstain from lobbying the Indian government for more stringent intellectual property regulation. This would have major negative impact on access to medicines for disadvantaged patients and would undermine competition with generic equivalent medicines. These particular issues are currently being negotiated in the framework of bilateral free-trade agreements between India and the European Union, and the European Free Trade Association.
The Open Letter follows a public call made by Patrick Durisch, health programme Coordinator of Bern Declaration, a HAI Europe member organisation, during the Annual General Meeting of Novartis’ shareholders last Tuesday. Durisch underlined the negative consequences of this judicial saga:
“The stakes go far beyond the granting of the patent for this anticancer drug. This action aims at weakening a public health safeguard clause – section 3(d) of the Indian Patents Act – which limits the multiplication of abusive or useless patents on an already-known substance”, said Mr Durisch. “Without this disposition, access to affordable medicines would be threatened in most developing countries, since India is one of the primary suppliers of generic medicines worldwide, in particular in the field of HIV/AIDS.”